<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251754</url>
  </required_header>
  <id_info>
    <org_study_id>APLAC001</org_study_id>
    <nct_id>NCT04251754</nct_id>
  </id_info>
  <brief_title>The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project</brief_title>
  <official_title>The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is currently lack of collaborative data on the epidemiology, clinicopathologic features
      and treatment outcome of newly diagnosed and relapsed APL in Asia. In addition, there is lack
      of data comparing oral- As2O3-based regimens with other treatment approaches, including
      intravenous As2O3,in the frontline or relapsed setting. With the long-term data of oral-As2O3
      based regimen for APL available from Hong Kong, retrospective and prospective comparison with
      other treatment approaches in other Asian countries will generate important information to
      pave the way for widespread application of oral-As2O3 outside Hong Kong.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q24;21) and the fusion gene
      PML-RARA.1 In newly-diagnosed patients, optimal supportive care together with the use of
      all-trans retinoic acid (ATRA) and chemotherapy results in first complete remission (CR1) in
      excess of 90% with durable remissions in about 80% of patients.Arsenic trioxide (As2O3) given
      intravenously (i.v.-As2O3) is highly efficacious for APL in first relapse (R1), inducing
      second complete remission (CR2) in more than 90% of patients. We have formulated an oral
      preparation of As2O3 (oral-As2O3), and shown that it is efficacious for APL in R1, giving CR2
      rates of more than 90% in both adults and children. For patients in CR2, a 2-year maintenance
      with oral-As2O3 results in durable remission and long-term survivals in more than 60% and 70%
      of patients respectively strongly suggesting that hematopoietic stem cell transplantation
      (HSCT) could be obviated in such patients. With these results, we implemented oral-As2O3
      maintenance in CR1 in Hong Kong and demonstrated very favourable overall-survival (OS) and
      leukemia-free-survival (LFS). This implied that that prolonged oral-As2O3 treatment may
      prevent relapses.

      Meanwhile, i.v.-As2O3 has also been tested in the frontline treatment of newly-diagnosed
      APL.These studies employed different strategies, recruiting a mixture of low-, intermediate-
      to high-risk patients and placing i.v.-As2O3 in induction and/or consolidation. During
      induction, i.v.-As2O3 was combined with ATRA, with additional gemtuzumab ozogamicin (an
      anti-CD33 immunoconjugate) or chemotherapy. During consolidation, i.v.-As2O3 was combined
      with conventional chemotherapy. Their results all indicated that frontline use of i.v.-As2O3
      in induction and/or consolidation improved the outcome of newly-diagnosed APL patients.
      However, with quite diverse protocols and the enrollment in some studies of only patients
      with low to intermediate risks, and in other studies of patients with all risk categories;
      the optimal strategy of employing i.v.-As2O3 in newly-diagnosed APL remains to be defined. We
      have tested oral- As2O3 in combination with ATRA, ascorbic acid (AAA) with daunorubicin in
      both low-risk and high-risk APL with 3 year LFS and OS of both 100%.

      With the impressive results of oral-As2O3-based regimen in newly diagnosed and relapsed APL,
      an important future perspective is the application of this relatively economical and
      convenient approach to the treatment of patients with APL in Asia and other developing
      countries around the world where the cost and availability of intravenous formulation of
      As2O3 is a concern. There is currently lack of collaborative data on the epidemiology,
      clinicopathologic features and treatment outcome of newly diagnosed and relapsed APL in Asia.
      In addition, there is lack of data comparing oral- As2O3-based regimens with other treatment
      approaches, including intravenous As2O3,in the frontline or relapsed setting. With the
      long-term data of oral-As2O3 based regimen for APL available from Hong Kong, retrospective
      and prospective comparison with other treatment approaches in other Asian countries will
      generate important information to pave the way for widespread application of oral-As2O3
      outside Hong Kong.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survivals</measure>
    <time_frame>60 months</time_frame>
    <description>The primary outcome measures in this study include the overall survival (OS) and the relapse-free survival (RFS). OS is defined as the time (in months) from diagnosis to death from any cause (event) or latest follow-up. RFS is defined as the time from first complete remission (CR)/complete remission with incomplete haematological recovery (CRi) to first hamatologic relapse or molecular relapse (R1) (event), death from any cause (event) or latest follow-up (censor). CR, CRi, treatment failure, haematologic relapse are defined according to the 2017 European LeukemiaNet (ELN) recommendations. A molecular relapse is defined as recurrence of measurable residual disease (MRD) by reverse-transcriptase polymerase chain reaction (RT-PCR) or real-time quantitative PCR (qRT PCR). A single MRD positivity must be confirmed by performing the molecular assay within 2 weeks.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This is a retrospective-prospective cohort study for all patients diagnosed with acute
        promyelocytic leukaemia since 2010 in Hong Kong and participating countries in Asia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients aged 18 or above

          -  Acute promyelocytic leukaemia with PML/RARA

          -  Acute myeloid leukaemia with variant RARA translocation

        Exclusion criteria:

        -Acute myeloid leukaemia without PML/RARA or variant RARA translocation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harinder Gill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harinder Singh Harry Gill, MD</last_name>
    <phone>+852 22554542</phone>
    <email>gillhsh@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medicine, the University of Hong Kong, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harinder Singh Harry Gill, MD</last_name>
      <phone>+852 22554254</phone>
      <email>gillhsh@hku.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <results_reference>
    <citation>Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009 Dec 10;114(25):5126-35. doi: 10.1182/blood-2009-07-216457.</citation>
    <PMID>19797519</PMID>
  </results_reference>
  <results_reference>
    <citation>Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002 Dec 15;100(13):4298-302. Epub 2002 Aug 15.</citation>
    <PMID>12393590</PMID>
  </results_reference>
  <results_reference>
    <citation>Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, Ludwig WD, Staib P, Aul C, Grüneisen A, Kern W, Reichle A, Serve H, Berdel WE, Braess J, Spiekermann K, Wörmann B, Sauerland MC, Heinecke A, Hiddemann W, Hehlmann R, Büchner T; German AML Cooperative Group. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009 Dec;23(12):2248-58. doi: 10.1038/leu.2009.183. Epub 2009 Sep 10.</citation>
    <PMID>19741727</PMID>
  </results_reference>
  <results_reference>
    <citation>Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 28;116(17):3171-9. doi: 10.1182/blood-2010-03-276196. Epub 2010 Jul 19.</citation>
    <PMID>20644121</PMID>
  </results_reference>
  <results_reference>
    <citation>Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009 Jun 1;27(16):2668-76. doi: 10.1200/JCO.2008.18.4119. Epub 2009 May 4.</citation>
    <PMID>19414681</PMID>
  </results_reference>
  <results_reference>
    <citation>Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999 Nov 15;94(10):3315-24.</citation>
    <PMID>10552940</PMID>
  </results_reference>
  <results_reference>
    <citation>Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 Sep 15;19(18):3852-60.</citation>
    <PMID>11559723</PMID>
  </results_reference>
  <results_reference>
    <citation>Au WY, Li CK, Lee V, Yuen HL, Yau J, Chan GC, Ha SY, Kwong YL. Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients. Pediatr Blood Cancer. 2012 Apr;58(4):630-2. doi: 10.1002/pbc.23306. Epub 2011 Sep 2.</citation>
    <PMID>21898784</PMID>
  </results_reference>
  <results_reference>
    <citation>Gill H, Yim R, Lee HKK, Mak V, Lin SY, Kho B, Yip SF, Lau JSM, Li W, Ip HW, Hwang YY, Chan TSY, Tse E, Au WY, Kumana CR, Kwong YL. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. Cancer. 2018 Jun 1;124(11):2316-2326. doi: 10.1002/cncr.31327. Epub 2018 Mar 26.</citation>
    <PMID>29579321</PMID>
  </results_reference>
  <results_reference>
    <citation>Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, Lau JS, Kwong YL. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood. 2011 Dec 15;118(25):6535-43. doi: 10.1182/blood-2011-05-354530. Epub 2011 Oct 12.</citation>
    <PMID>21998212</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7. doi: 10.1073/pnas.0813280106. Epub 2009 Feb 18.</citation>
    <PMID>19225113</PMID>
  </results_reference>
  <results_reference>
    <citation>Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874.</citation>
    <PMID>23841729</PMID>
  </results_reference>
  <results_reference>
    <citation>Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.</citation>
    <PMID>28003274</PMID>
  </results_reference>
  <results_reference>
    <citation>Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. Epub 2012 Jun 19.</citation>
    <PMID>22715121</PMID>
  </results_reference>
  <results_reference>
    <citation>Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.</citation>
    <PMID>27400939</PMID>
  </results_reference>
  <results_reference>
    <citation>Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. doi: 10.1182/blood-2010-02-269621. Epub 2010 Aug 12.</citation>
    <PMID>20705755</PMID>
  </results_reference>
  <results_reference>
    <citation>Gill H, Kumana CR, Yim R, Hwang YY, Chan TSY, Yip SF, Lee HKK, Mak V, Lau JSM, Chan CC, Kho B, Wong RSM, Li W, Lin SY, Lau CK, Ip HW, Leung RYY, Lam CCK, Kwong YL. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study. Cancer. 2019 Sep 1;125(17):3001-3012. doi: 10.1002/cncr.32180. Epub 2019 May 15.</citation>
    <PMID>31090936</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

